Gilead Plays Up Its Strength As Market Awaits Business Development Moves

Hiring new head of oncology away from Novartis has some watchers expecting cancer-focused business development by Gilead, but the company still thinks it can grow its HCV and HIV franchises and win the day with multiple candidates in NASH.

chess

Gilead Sciences Inc.’s main purpose for its presentation at the JP Morgan Healthcare Conference Jan. 9 seemed to be a show of strength, with CEO John Milligan discussing remaining opportunities in hepatitis C and HIV and the ways his company might study its three mid-stage non-alcoholic steatohepatitis (NASH) candidates together as combination therapy.

With sales of its blockbuster HCV franchise slowing, stakeholders have looked to Gilead for signals as to how it might...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.